Asthma
📧 Sign up to get email alerts when something new happens for Asthma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-06-01FDA Approved: ALBUTEROL SULFATE — Original Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved Hikma Pharmaceuticals USA Inc.'s original application for albuterol sulfate. This approval makes a generic albuterol sulfat…
-
FDA approval · 2021-04-06FDA Approved: BUDESONIDE INHALATION SUSPENSION — Supplemental Application (Cipla USA Inc.)
The FDA approved a supplemental application for budesonide inhalation suspension from Cipla USA Inc. This approval adds or modifies the prod…
-
FDA approval · 2021-03-31FDA Approved: BUDESONIDE INHALATION — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for Budesonide Inhalation by Amneal Pharmaceuticals of New York LLC.
-
FDA approval · 2021-03-29FDA Approved: BUDESONIDE INHALATION — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application for Budesonide Inhalation from Lupin Pharmaceuticals, Inc., approving changes to the approved generi…
-
FDA approval · 2021-02-22FDA Approved: SINGULAIR — Supplemental Application (Organon LLC)
The FDA has approved a supplemental application for Singulair (montelukast) from Organon LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-02-16FDA Approved: ASMANEX — Supplemental Application (Organon LLC)
FDA approved a supplemental application for ASMANEX (mometasone furoate) submitted by Organon LLC. The supplement pertains to the inhaled co…
-
FDA approval · 2021-01-29FDA Approved: MONTELUKAST — Supplemental Application (XLCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for Montelukast from XLCare Pharmaceuticals Inc., approving changes to the generic product under…
-
FDA approval · 2021-01-25FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for Accord Healthcare Inc.'s montelukast sodium product under ANDA 202717.
-
FDA approval · 2021-01-14FDA Approved: ALBUTEROL SULFATE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application from Lupin Pharmaceuticals for albuterol sulfate, confirming approval of a generic inhalation produc…
-
FDA approval · 2021-01-06FDA Approved: QVAR REDIHALER — Supplemental Application (Teva Respiratory, LLC)
The FDA approved Teva Respiratory's supplemental application for QVAR REDIHALER (beclomethasone dipropionate HFA). The action pertains to a …
-
FDA approval · 2020-12-17FDA Approved: FLUTICASONE PROPIONATE AND SALMETEROL — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approves Hikma's generic inhalation powder combination of fluticasone propionate and salmeterol. It is indicated for the treatment of as…
-
FDA approval · 2020-11-24FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved Torrent Pharmaceuticals Limited's supplemental application for montelukast sodium. This action grants regulatory approval for c…
-
FDA approval · 2020-11-10FDA Approved: PROVOCHOLINE — Supplemental Application (Methapharm Inc.)
The FDA approved a supplemental application for Provocholine (methacholine chloride) from Methapharm Inc., supporting its continued use as a…
-
FDA approval · 2020-11-10FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Dr.Reddy's Laboratories Limited)
The FDA approved a supplemental application for montelukast sodium from Dr. Reddy's Laboratories Limited, under an ANDA.
-
FDA approval · 2020-11-10FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for Montelukast Sodium from Dr. Reddy's Laboratories Limited, granting continued approval of a gener…
-
FDA approval · 2020-10-22FDA Approved: ALBUTEROL — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approves the original application for ALBUTEROL by Zydus Pharmaceuticals USA Inc., establishing a generic albuterol product.
-
FDA approval · 2020-10-20FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA Inc.'s supplemental application for Montelukast Sodium, marking approval of a generic montelukast product und…
-
FDA approval · 2020-10-20FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA Inc.'s supplemental application for Montelukast Sodium, authorizing a generic Montelukast product.
-
FDA approval · 2020-10-20FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved a supplemental application for Montelukast Sodium (ANDA 203432) from Ajanta Pharma USA Inc., granting approval of this generic …
-
FDA approval · 2020-10-08FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application to allow Lannett Company, Inc. to market a generic Montelukast Sodium product (ANDA 200405).
-
FDA approval · 2020-10-05FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for Montelukast Sodium by Torrent Pharmaceuticals Limited (ANDA 201515).
-
FDA approval · 2020-10-05FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Torrent Pharmaceuticals Limited)
The FDA approved Torrent Pharmaceuticals Limited's supplemental application for montelukast sodium, authorizing the regulatory action for th…
-
FDA approval · 2020-09-29FDA Approved: PROAIR DIGIHALER — Supplemental Application (Teva Respiratory, LLC)
FDA approved a supplemental application for ProAir Digihaler (albuterol sulfate) from Teva Respiratory, LLC.
-
FDA approval · 2020-09-29FDA Approved: ALBUTEROL SULFATE — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a supplemental application for ALBUTEROL SULFATE submitted by Padagis Israel Pharmaceuticals Ltd.
-
FDA approval · 2020-09-25FDA Approved: NUCALA — Supplemental Application (GlaxoSmithKline LLC)
FDA approves a supplemental application for NUCALA (mepolizumab) submitted by GlaxoSmithKline LLC.